Is Legal Marijuana Really At Risk Under Trump?


Kelly Weimert

March 29th, 2018

Policy


With recreational and medicinal marijuana becoming increasingly legal across the United States, it’s certainly an exciting time for both cannabis investors and enthusiasts. But before making any moves in this industry, it’s important to be aware of the associated risks, many of which come from the Trump administration’s stance on marijuana reform.

Trump’s Early Stance on Marijuana

It’s no secret that President Trump’s opinions are wavering and volatile on most matters, and cannabis is no exception. During his campaign for presidency, Trump stated clearly that he was “in favor of medical marijuana 100 percent” and that marijuana policy, in general, should be left up to the states without federal interference.

In February of 2017, one month after Trump became president, former White House spokesperson, Sean Spicer, told reporters that medical use marijuana wasn’t a concern for the administration. Spicer said, “the president understands the pain and suffering that many people go through who are facing especially terminal diseases and the comfort that some of these drugs, including medical marijuana, can bring to them.” However, according to Spicer, recreational marijuana is “a very, very different subject” and “greater enforcement” of federal cannabis laws could be on the horizon.

The fact that Trump seemingly broke his campaign promise to keep federal hands out of state marijuana policies is likely largely influenced by his appointment of Jeff Sessions to attorney general.

Attorney General Jeff Sessions’ Vehement Marijuana Opposition

Attorney General Jeff Sessions is notorious for having an ignorant view on marijuana, going so far as to say, “good people don’t smoke marijuana.” And when referring to racist hate group, the Ku Klux Klan, Sessions has said, “I thought those guys were okay until I learned they smoked pot.”

Since becoming the head of the Department of Justice, Sessions is living up to his reputation. Earlier this year, he led the charge in rescinding the Cole memo, a directive that was put in place by the Obama Administration advising federal prosecutors not to pursue cases against marijuana businesses that were operating in legal cannabis states.

That being said, like many of Trump’s appointments, Sessions role as attorney general could be in jeopardy. After Sessions recused himself from the investigation into Trump’s potential collusion with Russia, Trump said, “So Jeff Sessions takes the job, gets into the job, recuses himself… How do you take a job and then recuse yourself? If he would have recused himself before the job, I would have said, ‘Thanks, Jeff, But I can’t, you know. I’m not going to take you.’ It’s extremely unfair, and that’s a mild word, to the president.”

Since then, tensions between Sessions and Trump are well documented, including many insulting tweets from the president directed at the attorney general as well as reported threats by Sessions to resign numerous times.

Trump Administration’s Lack of Evidence-Based Marijuana Policy

Even if Sessions is to be removed from his role as attorney general, advocates of marijuana reform should be wary of the lack of evidence-based marijuana policymaking in the Trump Administration. Despite Trump being vocal about wanting to tackle the current opioid addiction crisis in the country, he and his administration seem to have little understanding of how to do so.

Increasing research suggests that marijuana is a healthier and less addictive alternative to pain management than opioids, and there are lower rates of fatal opioid overdose in states where medical marijuana is legal. However, the Trump administration seems to have an opposing view to clinical research, with Sean Spicer once linking marijuana legalization to the opioid crisis—a statement that is entirely unfounded and, in fact, the inverse of what current research suggests.

Recent Good News About Marijuana Reform

Even though Trump and his appointees haven’t done much, if anything, to move marijuana reform forward, there’s still plenty of hope for both marijuana investors and enthusiasts.

First, there’s the fact that Americans as a whole are increasingly in support of marijuana legalization. According to Pew Research, 61% of Americans believe cannabis should be legalized, a number that’s been on a steady increase over the past decade and up from 31% in 2000. That number is certainly large enough for members of Congress to pay attention if they’re hoping for reelection.

Even better, on March 23rd of this year, Trump signed a $1.3 trillion spending measure that renews protections for medical marijuana providers and patients. The passage of this bill means that the Rohrabacher-Blumenauer provision is still in effect. Rohrabacher-Blumenauer prohibits the use of federal funds to prevent states from “implementing their own state laws that authorize the use, distribution, possession or cultivation of medical marijuana.” Many marijuana advocates feared that this provision would expire under the Trump administration, so its renewal is encouraging.

Bottom Line

Like most issues, Trump’s stance on marijuana reform is unclear and continuously changing, but the people he’s appointed to office, namely Attorney General Jeff Sessions, are vehemently opposed to marijuana legalization. However, proponents of legalization can find solace in the fact that the majority of Americans are in favor of legalization and recent moves by Congress indicate that there’s no immediate threat to legal medical marijuana at this time.

Kelly Weimert

About Kelly Weimert

Kelly is a full-time freelance writer based in Austin, TX. A happy hybrid of geek and hippie, when she's not nestled into her couch crankin' out crafty prose with her miscreant Chihuahua, you can find her frolicking outside to keep her sanity in check.


Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading